CTI BioPharma
CTIC
$9.09
Share price
0.00%
Change (1 day)
30.79%
Change (1 year)
Categories
P/S ratio for CTI BioPharma (CTIC)
P/S ratio as of April 2024 (TTM): 15.8
According to CTI BioPharma 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 15.8216. At the end of 2023 the company had a P/S ratio of 7.31.
P/S ratio history for CTI BioPharma from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 7.31 | -48.3% |
| 2022 | 14.1 | |
| 2021 | N/A | |
| 2020 | N/A | -100% |
| 2019 | 27.4 | 1568.81% |
| 2018 | 1.64 | -64.16% |
| 2017 | 4.58 | 128.47% |
| 2016 | 2.00 | -90.64% |
| 2015 | 21.4 | 208.27% |
| 2014 | 6.94 | -13.36% |
| 2013 | 8.01 | |
| 2012 | N/A | |
| 2011 | N/A | -100% |
| 2010 | 931 | -88.93% |
| 2009 | > 1000 | 1174734.83% |
| 2008 | 0.7160 | -99.91% |
| 2007 | 761 | -75.95% |
| 2006 | > 1000 | 32410.49% |
| 2005 | 9.73 | -42.02% |
| 2004 | 16.8 | 41.05% |
| 2003 | 11.9 | -15.38% |
| 2002 | 14.1 | -89.23% |
| 2001 | 131 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.96 | -74.96% | 🇨🇭 Switzerland |
 Eli Lilly LLY | 20.4 | 28.94% | 🇺🇸 USA |
 Amgen AMGN | 5.19 | -67.17% | 🇺🇸 USA |
 Baxter BAX | 1.37 | -91.34% | 🇺🇸 USA |
 Incyte INCY | 3.11 | -80.35% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.20 | -86.09% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.9471 | -94.01% | 🇮🇱 Israel |